C4 Therapeutics and Roche Strengthen Partnership with $1 Billion Cancer Deal

• C4T will receive $20 million upfront for two programs, with potential for additional payments if Roche exercises an option for a third target
• C4T is eligible for over $1 billion in discovery, regulatory, and commercial milestone payments, plus tiered royalties on future sales
• Roche will handle all preclinical and clinical development as well as commercialization of the DAC candidates targeting undisclosed oncology targets

Summary

Key Deal Terms:

C4 Therapeutics (C4T) and Swiss pharmaceutical giant Roche have expanded their partnership with a cancer drug development agreement potentially worth over $1 billion. C4T will receive a $20 million upfront payment for two collaborative programs, with an additional payment available if Roche exercises an option for a third target. The company is eligible for more than $1 billion in discovery, regulatory, and commercial milestone payments, plus tiered royalties on future sales.

Technology Focus:

The collaboration centers on developing degrader-antibody conjugates (DACs), an emerging class of cancer therapeutics that combine antibody-drug conjugation with targeted protein degradation technology. The programs will target undisclosed oncology-specific applications exclusive to this agreement.

Responsibilities:

Roche will lead the advancement of DAC candidates through preclinical and clinical development stages, as well as handle commercialization efforts. This structure allows C4T to leverage Roche's extensive development and commercial infrastructure while maintaining financial upside through milestones and royalties.

Partnership History:

This agreement represents the third collaboration between the two companies, extending a relationship that originated in 2016. The strengthened partnership demonstrates Roche's continued confidence in C4T's protein degradation platform and the therapeutic potential of DAC technology.

Market Implications:

The deal highlights growing pharmaceutical industry interest in targeted protein degradation as a cancer treatment modality. For C4T, the agreement provides significant non-dilutive funding and validates its technology platform, while Roche gains access to innovative oncology assets that complement its existing cancer portfolio.